Altimmune appoints former GSK executive Catherine Sohn to board of directors

Altimmune, Inc.

Catherine Sohn, Pharm.D., appointed to Altimmune's Board effective March 23, 2023.
Dr. Sohn currently serves on boards of Jazz Pharma, Axcellea Health, and Maze Therapeutics.
She was formerly SVP Worldwide Business Development at GSK's Consumer Healthcare division.
Received initial option award for 47,000 shares and annual cash retainer of $40,000.
CEO Vipin Garg says her experience in peptide therapeutics for obesity and liver disease will be valuable.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine Sohn

Director

ALT · Altimmune, Inc.

Effective: 2023-03-23
Filed: March 27, 2023, 7:59 PM ET

appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Catherine Sohn was appointed as Director at Altimmune, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.